The landscape of immune checkpoint inhibitor clinical trials in glioblastoma: A systematic review.

ABSTRACT:

Background

Glioblastoma is characterized by rapid tumor growth and high invasiveness. The tumor microenvironment of glioblastoma is highly immunosuppressive with both intrinsic and adaptive resistance mechanisms that result in disease recurrence despite current immunotherapeutic strategies.

Methods

In this systematic review of clinical trials involving immunotherapy for glioblastoma using ClinicalTrials.gov and PubMed databases from 2016 and onward, we explore immunotherapeutic modalities involving immune checkpoint blockade (ICB).

Results

A total of 106 clinical trials were identified, 18 with clinical outcomes. ICB in glioblastoma has failed to improve overall survival compared to the current standard of care, including those therapies inhibiting multiple checkpoint

SUBMITTER: Schonfeld E 

PROVIDER: S-EPMC11555435 | biostudies-literature | 2024 Jan-Dec

REPOSITORIES: biostudies-literature